Hormonal therapy in aid for women with venous thrombosis
According to a study, venous thrombosis when treated with hormone therapy may be a subject of risk. It was revealed during the study that though this ailment is rare but it can prove to be fatal as it can increase on an exponential basis to form blood clots deep inside the vein during menopause.
The research team including Mayo Clinic researchers and led by Virginia Miller remarked that a novel concept for focusing on blood platelets for defining the risk of thrombosis has been developed. This research was discussed by Miller at a conference sponsored by the American Physiological Society (APS).
From News-Medical.Net:
The study focuses on platelets, which are cellular fragments in the blood. Platelets have a phenotype (i.e., a set of physical characteristics) that change and it is known that hormones affect platelet change. The team is examining what happens to platelets in the presence of hormones , whether platelet microvesicles occur more frequently as a result, if a change is triggered by infection, and what may account for thrombotic risk in one woman over another.
The study design takes into account the researchers, belief that three forces , an injury, a platelet effect at the injury, and the inflammation that affects the platelet and the vessel wall , are involved in the development of thrombotic risk.
The study builds on the team’s earlier findings in an animal model. They are applying the earlier results to a human population for the first time using blood taken from the women enrolled in the KEEPS trial. Depending upon the results from this group, a larger trial of 720 samples will be examined.
Depending on the results of this study, the researchers may examine the relationship of platelet activity, inflammation, and cardiovascular risk (CV) in men. It is well known that men have a higher risk factor for cardiovascular disease (CVD) than do females, and arterial clots, rather than venous clots, are a greater concern in the presence of CVD. Since men carry the female hormone estrogen as well as the male hormone testosterone, some of the findings from the female KEEPS study may shed light on these mechanisms involving men.
Miller was of the view that the research can prove to be beneficial for members of the medical fraternity in defining risk profiles with anticipation to define tools that can offer hormonal therapy to female patients in commensuration with a risk for venous thrombosis.
Tags: cardiovascular risk, hormonal therapy, platelet aggregation, sex steroids, venous thrombosis
Recent Comments